Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.
The San Diego startup said Thursday that its therapy, ValloVax™, will be tested in a Phase 1/2 trial against non-small cell lung cancer once the U.S. Food and Drug Administration approves the application.
ValloVax™ targets proteins found in blood vessels induced by cancer that are not present in ordinary blood vessels. In mouse models, the vaccine inhibited tumor formation in melanoma, breast and lung cancer.
UCSD brain cancer specialist Dr. Santosh Kesari said he’s asked Batu if he can take part in the clinical trial.
“The innovative thing about this technology is that you’re combining two powerful, validated technologies in one: angiogenesis inhibitors and immunotherapy,” Kesari said. “I think it has a lot of potential.”